Serial reactivity of post-DLI serum with myeloma-associated antigens
Gene products . | Screening serum . | Pre-BMT . | Pre-DLI . | 2 mo . | 4 mo . | 6 mo . | 1 y . | 2 to 2.6 y . |
|---|---|---|---|---|---|---|---|---|
| KIAA0053 | E | - | - | ++ | + | + | - | - |
| BCMA | E | - | - | + | ++++ | +++ | ++ | + |
| FLJ10330 | E | - | - | + | +++ | ++ | + | + |
| FLJ10534 | E | - | - | - | + | + | + | - |
| SON DNA | E | - | - | NA | ++ | ++ | + | + |
| DHA | E + L | - | - | ++ | ++++ | +++ | +++ | ++ |
| Homer-3 | E + L | - | - | NA | ++ | ++ | ++ | + |
| Bif-1 | E + L | - | - | + | ++ | ++++ | +++ | ++ |
| ROCK-1 | L | - | - | - | - | - | + | ++++ |
| Similar to hepatoma-derived growth factor | L | - | - | - | + | + | + | ++++ |
| Heterogeneous nuclear ribonucleoprotein D-like | L | - | - | + | + | + | ++ | ++ |
| SFRS | L | - | - | NA | + | + | ++ | ++ |
| AT-rich sequence-binding protein | L | - | - | NA | + | ++ | ++ | ++ |
Gene products . | Screening serum . | Pre-BMT . | Pre-DLI . | 2 mo . | 4 mo . | 6 mo . | 1 y . | 2 to 2.6 y . |
|---|---|---|---|---|---|---|---|---|
| KIAA0053 | E | - | - | ++ | + | + | - | - |
| BCMA | E | - | - | + | ++++ | +++ | ++ | + |
| FLJ10330 | E | - | - | + | +++ | ++ | + | + |
| FLJ10534 | E | - | - | - | + | + | + | - |
| SON DNA | E | - | - | NA | ++ | ++ | + | + |
| DHA | E + L | - | - | ++ | ++++ | +++ | +++ | ++ |
| Homer-3 | E + L | - | - | NA | ++ | ++ | ++ | + |
| Bif-1 | E + L | - | - | + | ++ | ++++ | +++ | ++ |
| ROCK-1 | L | - | - | - | - | - | + | ++++ |
| Similar to hepatoma-derived growth factor | L | - | - | - | + | + | + | ++++ |
| Heterogeneous nuclear ribonucleoprotein D-like | L | - | - | + | + | + | ++ | ++ |
| SFRS | L | - | - | NA | + | + | ++ | ++ |
| AT-rich sequence-binding protein | L | - | - | NA | + | ++ | ++ | ++ |
E indicates early; L, late; NA, sample not available; -, negative. Other table symbols (+, -) are described in the footnote to Table 5.